Neurogen has generated a portfolio of compelling new drug candidates through its Accelerated Intelligent Drug Discovery system, its expertise in cellular functional assays, and its depth in medicinal chemistry.
In addition, the company's proprietary technology, Accelerated Intelligent Drug Discovery (AIDD), is the result of a successful collaboration with Merck for VR-1 research programs.
President and Chief Executive Officer of Neurogen, said, "The combination of Neurogen's novel corticotrophin releasing factor chemotype, the substantial quantity of promising chemical leads from our Accelerated Intelligent Drug Discovery system, and Aventis' impressive development and commercial expertise comprise all the right elements for a successful effort.
Neurogen continues to generate a portfolio of compelling new drug candidates through its Accelerated Intelligent Drug Discovery (AIDD(TM)) system, its expertise in cellular functional assays, and its depth in medicinal chemistry.
Neurogen has generated a portfolio of compelling new drug candidates through its Accelerated Intelligent Drug Discovery (AIDD(TM)) system, its expertise in cellular functional assays, and its depth in medicinal chemistry.
Neurogen has generated a portfolio of compelling new drug candidates through its Accelerated Intelligent Drug Discovery (AIDD(TM)) system, its expertise in cellular functional assays, and its depth in medicinal chemistry.
